Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GS 4104 neuraminidase inhibitor: Phase III

GILD partner F. Hoffmann-La Roche Ltd. presented data from a U.S. Phase III treatment study of GS 4104 in 629 patients, showing a 30 percent reduction in illness. Median disease duration was 2.9 days in both the 75 mg (p=0.0001) and 150 mg (p=0.001)

Read the full 443 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers